Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 12/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 7/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.34 |
| ▸ | ABCC1 | P33527 | 3/20 | 0.34 |
| ▸ | MYC | P01106 | 1/20 | 0.34 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.33 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.33 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22908161 | 0.99 | ABCG2 (0.38) | ABCG2ABCB1HTTPDK2ABCC1 | |
| SCHEMBL21151547 | 0.96 | ABCG2 (0.37) | ABCG2ABCB1HTTPDK2ABCC1 | |
| SCHEMBL21151546 | 0.96 | ABCG2 (0.37) | ABCG2ABCB1HTTPDK2ABCC1 | |
| SCHEMBL21343706 | 0.94 | ABCG2 (0.37) | ABCG2ABCB1HTTPDK2ABCC1 | |
| SCHEMBL24905526 | 0.94 | ABCG2 (0.37) | ABCG2ABCB1HTTPDK2ABCC1 | |
| SCHEMBL21701688 | 0.94 | ABCG2 (0.37) | ABCG2ABCB1HTTPDK2ABCC1 | |
| SCHEMBL23256520 | 0.93 | ABCG2 (0.34) | ABCG2ABCB1HTTPDK2ABCC1 | |
| SCHEMBL22908160 | 0.93 | PDK2 (0.40) | ABCG2HTTPDK2ALDH1A3GABRA1 | |
| SCHEMBL21701684 | 0.92 | ABCG2 (0.38) | ABCG2ABCB1HTTPDK2ABCC1 | |
| SCHEMBL21343151 | 0.92 | ABCG2 (0.34) | ABCG2ABCB1HTTPDK2ABCC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11542258-B2 | Heterocyclic compound and organic light emitting device comprising the same | LG CHEM, LTD. (KR) | 2023-01-03 | — | — | US | disclosed |
| US-20210217967-A1 | ORGANIC LIGHT EMITTING DEVICE | LG CHEM, LTD. (KR) | 2021-07-15 | — | — | US | disclosed |
| US-20200262825-A1 | NOVEL HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING THE SAME | LG CHEM, LTD. (KR) | 2020-08-20 | — | — | US | disclosed |
| US-20190214571-A1 | ORGANIC LIGHT EMITTING DEVICE | LG CHEM, LTD. (KR) | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190214571-A1 | ORGANIC LIGHT EMITTING DEVICE | PPOX, ERO1A, HMOX2 | ABCG2 3903/4885ABCB1 1123/4885HTT 33/4885 |
| US-20200262825-A1 | NOVEL HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING THE SAME | CRY1, CYP1A1, CYP1B1 | ABCG2 1542/4885ABCB1 850/4885HTT 3350/4885 |
| US-11542258-B2 | Heterocyclic compound and organic light emitting device comprising the same | CYP1A1, CRY1, CYP1B1 | ABCG2 1229/4885ABCB1 579/4885HTT 2643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.